Metoclopramida Labesfal (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide blocks dopamine D2 receptors in the chemoreceptor trigger zone, antagonizes 5‑HT3 receptors, and stimulates 5‑HT4 receptors. This combination suppresses central vomiting signals while increasing acetylcholine release, which promotes coordinated gastrointestinal motility.

The appropriate dose of Metoclopramida Labesfal is determined by the prescribing clinician based on the patient’s condition, age, renal function and other individual factors. Dosage regimens are not standardized and should follow the prescriber’s instructions.

Safety data for metoclopramide in pregnancy are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult a healthcare professional before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many anti‑emetics by combining dopamine antagonism with serotonergic activity and a pro‑kinetic effect. Unlike pure 5‑HT3 antagonists such as ondansetron, it also enhances gastric motility, making it useful for conditions like gastroparesis, but it carries a higher risk of extrapyramidal side effects.

Metoclopramida Labesfal should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. No refrigeration is required for this oral formulation.

The product is taken orally, usually with or without food, as directed by a healthcare professional. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include extrapyramidal reactions such as acute dystonia, tardive dyskinesia with long‑term use, and rare occurrences of neuroleptic malignant syndrome. Patients should be monitored for muscle rigidity, involuntary movements, fever or altered mental status and seek immediate medical attention if these arise.

Metoclopramida Labesfal is contraindicated in individuals with known hypersensitivity to metoclopramide, those with gastrointestinal obstruction, perforation or hemorrhage, and patients with pheochromocytoma. Caution is also advised for patients with severe depression or seizure disorders.